Clinical Trials Arena December 6, 2024
Eve Thomas

Sentiment towards digital and AI tech in the clinical research sector remains positive, with “slow and steady” uptake.

A survey conducted by ICON has found sentiment towards artificial intelligence (AI) and digital tools in the clinical research sector is positive, with 49% of pharmaceutical and biotechnology companies employing AI and Big Data in their programs. This represents a 10% increase from the number recorded in ICON’s 2019 survey.

ICON has published the results in its new whitepaper –Digital disruption: Surveying the industry’s evolving landscape – looking to understand the trajectory of artificial intelligence (AI) and digital research within the clinical research field.

A total of 101 responses from biotech and pharmaceutical professionals across Europe and North America were considered.

The...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Big Data, Biotechnology, Pharma, Pharma / Biotech, Technology
Related Articles:
Mark Cuban: A Master Disrupter for American Healthcare
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
How has U.S. Spending on Health Care Changed Over Time?
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Merck enters $2B licensing deal for weight loss drug

Share This Article